Biofrontera Inc (BFRI) Stock Price, Quote & News

Latest News on BFRI

Jan 8, 2025, 9:50 AM EST - 10 days ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Dec 23, 2024, 9:30 AM EST - 26 days ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 3, 2024, 11:00 AM EST - 6 weeks ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 22, 2024, 9:10 AM EST - 2 months ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 14, 2024, 3:02 PM EST - 2 months ago

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:15 PM EST - 2 months ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 1, 2024, 11:55 AM EDT - 2 months ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Oct 31, 2024, 10:32 AM EDT - 2 months ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 3 months ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 7, 2024, 8:45 AM EDT - 3 months ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Sep 25, 2024, 10:45 AM EDT - 4 months ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 15, 2024, 1:34 PM EDT - 5 months ago

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:30 PM EDT - 5 months ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 9, 2024, 10:00 AM EDT - 5 months ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 7 months ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

May 16, 2024, 2:44 PM EDT - 8 months ago

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:45 PM EDT - 8 months ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 6, 2024, 10:30 AM EDT - 9 months ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:50 AM EDT - 9 months ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Mar 26, 2024, 4:30 PM EDT - 10 months ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 18, 2024, 12:13 PM EDT - 10 months ago

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 8:25 PM EDT - 11 months ago

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 6:10 PM EDT - 11 months ago

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 8, 2024, 9:00 AM EST - 11 months ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Mar 5, 2024, 7:30 AM EST - 11 months ago

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Feb 23, 2024, 8:40 AM EST - 11 months ago

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Feb 20, 2024, 8:10 AM EST - 11 months ago

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Feb 20, 2024, 8:05 AM EST - 11 months ago

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Feb 5, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Jan 11, 2024, 4:15 PM EST - 1 year ago

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

Nov 10, 2023, 1:54 PM EST - 1 year ago

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:10 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 3, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

Oct 31, 2023, 8:01 AM EDT - 1 year ago

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Oct 5, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

Aug 29, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Aug 28, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Aug 11, 2023, 10:12 AM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Aug 4, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

Jul 13, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

Jul 12, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

Jul 3, 2023, 9:15 AM EDT - 1 year ago

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

Jun 12, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

Jun 1, 2023, 9:15 AM EDT - 1 year ago

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

May 30, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

May 15, 2023, 9:50 AM EDT - 1 year ago

Market Cap	8.52M
Revenue (ttm)	34.07M
Net Income (ttm)	-20.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.08%
Debt to Equity Ratio	0.00

Volume	179,200
Avg Vol	1,081,732
Day's Range	N/A - N/A
Shares Out	7.75M
Stochastic %K	15%
Beta	0.27
Analysts	Strong Sell
Price Target	$11.50